Bixia Tang

Featured in: Favicon

frontiersin.org Favicon

amegroups.com Favicon

ejcancer.com Favicon

biorxiv.org Favicon

cco.amegroups.com

Articles

Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial

Oct 1, 2024 | jitc.bmj.com | Bixia Tang |Yu Chen |Yu Jiang |Meiyu Fang

MethodsThis multicenter, open-label, phase I clinical trial consisted of two parts—dose-escalation phase (part 1) and dose-expansion phase (part 2). Patients were enrolled from nine centers in China. Eligible participants were 18 years or older with histopathologically confirmed advanced or recurrent solid tumors per American Joint Committee on Cancer eighth edition (melanoma of uveal origin was not included).

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →